Clinical Trials in Ridgeland, Mississippi
16 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
Asthma
AstraZeneca200 enrolled116 locationsNCT05692180
Recruiting
Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Endometrial Hyperplasia
Bayer207 enrolled86 locationsNCT06904274
Recruiting
Phase 1Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals232 enrolled85 locationsNCT06649110
Recruiting
Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Coronavirus Disease (COVID-19)
Merck Sharp & Dohme LLC3,082 enrolled222 locationsNCT06667700
Recruiting
Phase 2
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Obesity, OverweightMobility DisabilityHOMA-IR
Veru Inc.200 enrolled10 locationsNCT07446998
Recruiting
Phase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
Opioid-use Disorder
Eli Lilly and Company465 enrolled57 locationsNCT07420283
Recruiting
Phase 2Phase 3
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated466 enrolled318 locationsNCT05312879
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 3
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Atopic Dermatitis
Organon and Co180 enrolled48 locationsNCT07265479
Recruiting
Phase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
AbbVie420 enrolled61 locationsNCT06810505
Recruiting
Phase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Episodic Migraine
AbbVie450 enrolled98 locationsNCT05711394
Recruiting
Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine
AbbVie1,059 enrolled124 locationsNCT05125302
Recruiting
Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Migraine
AbbVie496 enrolled106 locationsNCT06417775
Recruiting
Phase 2Phase 3
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
BioNTech SE4,292 enrolled134 locationsNCT05543616
Recruiting
Phase 3
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
EndometriosisUterine Fibroids
Sumitomo Pharma Switzerland GmbH1,000 enrolled120 locationsNCT05862272
Recruiting
Phase 3
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
COVID-19
Pfizer160 enrolled73 locationsNCT05261139